145 related articles for article (PubMed ID: 34881637)
1. IL-6 and IL-8 cytokines are associated with elevated prostate-specific antigen levels among patients with adenocarcinoma of the prostate at the Uganda Cancer Institute.
Katongole P; Sande OJ; Nabweyambo S; Joloba M; Kajumbula H; Kalungi S; Reynolds SJ; Ssebambulidde K; Atuheirwe M; Orem J; Niyonzima N
Future Oncol; 2022 Feb; 18(6):661-667. PubMed ID: 34881637
[No Abstract] [Full Text] [Related]
2. Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer.
Saylor PJ; Kozak KR; Smith MR; Ancukiewicz MA; Efstathiou JA; Zietman AL; Jain RK; Duda DG
Oncologist; 2012; 17(2):212-9. PubMed ID: 22302227
[TBL] [Abstract][Full Text] [Related]
3. Cytokine variations in patients with hormone treated prostate cancer.
Wise GJ; Marella VK; Talluri G; Shirazian D
J Urol; 2000 Sep; 164(3 Pt 1):722-5. PubMed ID: 10953133
[TBL] [Abstract][Full Text] [Related]
4. Prostate specific antigen testing: age-related interpretation in early prostate cancer detection.
McKenzie PR; Delahunt B; Kench JG; Ross B; Lam Q; deVoss K; Tran HA; Sikaris KA
Pathology; 2013 Jun; 45(4):343-5. PubMed ID: 23619589
[No Abstract] [Full Text] [Related]
5. Serum multi-cytokines screening identifies TRAIL and IL-10 as probable new biomarkers for prostate health index diagnostic utility adjustment in grey zone aggressive prostate cancer detection: A single-center data in China.
Chen H; Zhou J; Luo J; Wu Y; Qian Y; Shi Y; Qu F; Shi B; Ding J; Cui X; Yu Y
Front Immunol; 2022; 13():901176. PubMed ID: 36059480
[TBL] [Abstract][Full Text] [Related]
6. Association between immunosuppressive cytokines and PSA progression in biochemically recurrent prostate cancer treated with intermittent hormonal therapy.
Hawley JE; Pan S; Figg WD; Lopez-Bujanda ZA; Strope JD; Aggen DH; Dallos MC; Lim EA; Stein MN; Hu J; Drake CG
Prostate; 2020 Mar; 80(4):336-344. PubMed ID: 31899823
[TBL] [Abstract][Full Text] [Related]
7. [-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study.
Sokoll LJ; Wang Y; Feng Z; Kagan J; Partin AW; Sanda MG; Thompson IM; Chan DW
J Urol; 2008 Aug; 180(2):539-43; discussion 543. PubMed ID: 18550118
[TBL] [Abstract][Full Text] [Related]
8. Changes of plasma cytokines and chemokines expression level in nasopharyngeal carcinoma patients after treatment with definitive intensity-modulated radiotherapy (IMRT).
Jin YB; Zhang GY; Lin KR; Chen XP; Cui JH; Wang YJ; Luo W
PLoS One; 2017; 12(2):e0172264. PubMed ID: 28207826
[TBL] [Abstract][Full Text] [Related]
9. Elevation of cytokine levels in cachectic patients with prostate carcinoma.
Pfitzenmaier J; Vessella R; Higano CS; Noteboom JL; Wallace D; Corey E
Cancer; 2003 Mar; 97(5):1211-6. PubMed ID: 12599227
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological characteristics of androgen-dependent advanced prostate cancer patients with α2-macroglobulin deficiency.
Kanoh Y; Ohtani H; Egawa S; Baba S; Akahoshi T
Int J Oncol; 2012 Jul; 41(1):39-45. PubMed ID: 22576683
[TBL] [Abstract][Full Text] [Related]
11. Elevated IL-8, TNF-α, and MCP-1 in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival.
Sharma J; Gray KP; Harshman LC; Evan C; Nakabayashi M; Fichorova R; Rider J; Mucci L; Kantoff PW; Sweeney CJ
Prostate; 2014 Jun; 74(8):820-8. PubMed ID: 24668612
[TBL] [Abstract][Full Text] [Related]
12. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma.
Adler HL; McCurdy MA; Kattan MW; Timme TL; Scardino PT; Thompson TC
J Urol; 1999 Jan; 161(1):182-7. PubMed ID: 10037394
[TBL] [Abstract][Full Text] [Related]
13. Prostate detection possibility.
Gunby P
JAMA; 1999 Jun 23-30; 281(24):2274-5. PubMed ID: 10386541
[No Abstract] [Full Text] [Related]
14. Diagnostic and prognostic significance of prostate specific antigen and serum interleukin 18 and 10 in patients with locally advanced prostate cancer: a prospective study.
Dwivedi S; Goel A; Natu SM; Mandhani A; Khattri S; Pant KK
Asian Pac J Cancer Prev; 2011; 12(7):1843-8. PubMed ID: 22126577
[TBL] [Abstract][Full Text] [Related]
15. Research on the relationship between serum levels of inflammatory cytokines and non-small cell lung cancer.
Song XY; Zhou SJ; Xiao N; Li YS; Zhen DZ; Su CY; Liu ZD
Asian Pac J Cancer Prev; 2013; 14(8):4765-8. PubMed ID: 24083740
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer.
Zabransky DJ; Smith HA; Thoburn CJ; Zahurak M; Keizman D; Carducci M; Eisenberger MA; McNeel DG; Drake CG; Antonarakis ES
Prostate; 2012 Apr; 72(5):487-98. PubMed ID: 21748755
[TBL] [Abstract][Full Text] [Related]
17. Cytokines levels in prostate adenocarcinomas.
Bălăşoiu M; Turculeanu A; Avrămescu C; Comănescu V; Simionescu C; Mogoantă L
Rom J Morphol Embryol; 2005; 46(3):179-82. PubMed ID: 16444302
[TBL] [Abstract][Full Text] [Related]
18. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer.
Drachenberg DE; Elgamal AA; Rowbotham R; Peterson M; Murphy GP
Prostate; 1999 Oct; 41(2):127-33. PubMed ID: 10477909
[TBL] [Abstract][Full Text] [Related]
19. Relative value of prostate-specific antigen and prostatic acid phosphatase in diagnosis and management of adenocarcinoma of prostate. Ohio State University experience.
Drago JR; Badalament RA; Wientjes MG; Smith JJ; Nesbitt JA; York JP; Ashton JJ; Neff JC
Urology; 1989 Oct; 34(4):187-92. PubMed ID: 2477931
[TBL] [Abstract][Full Text] [Related]
20. Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer.
Michalaki V; Syrigos K; Charles P; Waxman J
Br J Cancer; 2004 Jun; 90(12):2312-6. PubMed ID: 15150588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
